ArticlePloS one2025
National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple factors challenge PCR test results for COVID-19 infection, and only symptomatic cases have been tested. Thus, a population-based seroprevalence study was necessary to determine the extent of missed cases. The objective of this study was to achieve a realistic infection rate in Iran and probe into some explanations behind being infected or not. In this population-based cross-sectional study, 16,610 adults aged more than 25 with valid serology sample results from 31 provinces from February to April 2021 were included. According to the ELISA kits based on the N antigen of SARS-CoV-2, the seroprevalence of IgG against SARS-CoV-2 in Iran was 20.63% (19.71-21.56) and 16.25% (15.11-17.41) based on two different corrections. The age-standardized seroprevalence was relatively high among Kurdistan [30.29% (26.04-34.55) and 28.31% (23-33.61)] and West Azarbayejan [29.33% (24.85-33.8) and 27.11% (21.52-32.68)]. Smoking, higher education, being underweight, male, and single were protective factors, and higher daily interactions was a risk for seropositivity. It is evident that reported infection rates have been misleading. Furthermore, several intervenable factors can predict the risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.